{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-006120","form_type":"8-K","ticker":"MNPR","cik":"0001645469","company_name":"Monopar Therapeutics","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.819197+00:00","generated_at":"2026-06-15T04:14:00.858176+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Monopar Q1 net loss $2.4M; camsirubicin dose-escalation continues; Validive trial discontinued","bullets":["Net loss of $2.4M ($0.19/share) for Q1 2023, vs $2.5M ($0.19/share) in Q1 2022.","Cash, equivalents and short-term investments $11.7M as of March 31, 2023; runway through June 2024.","Camsirubicin Phase 1b enrolling 5th dose cohort (650 mg/m²); no drug-related cardiotoxicity observed to date.","Validive Phase 2b/3 VOICE trial discontinued after DSMB found it did not meet 15% efficacy threshold.","MNPR-101 RIT preclinical studies show high tumor uptake; FIH imaging study targeted by end of 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-006120","json":"https://secwatch.observer/filing/0001654954-23-006120.json","markdown":"https://secwatch.observer/filing/0001654954-23-006120.md","text":"https://secwatch.observer/filing/0001654954-23-006120.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645469/000165495423006120/0001654954-23-006120-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645469/000165495423006120/mnpr_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:14:00.858176+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b3fbc231243a2f42aa79ebe15ce647ec639c4e56","claim":"Monopar Therapeutics reported first quarter ended March 31, 2023 results: net income $2.4 million, EPS $0.19 per share.","evidence_excerpt":"Net loss for the first quarter of 2023 was $2.4 million or $0.19 per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645469/000165495423006120/0001654954-23-006120-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Net income","value":"$2.4 million"},{"label":"EPS","value":"$0.19 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}